Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Preterm labor drugs under scrutiny: do they harm the fetal heart?

NCT ID NCT06904534

Knowledge-focused Sponsor: Sanliurfa Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 pregnant women between 24 and 34 weeks of pregnancy who are given either nifedipine or magnesium sulfate to stop preterm labor. Researchers use ultrasound to check the baby's heart function before and 48 hours after treatment. The goal is to see if these drugs have any unexpected effects on the fetal heart.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with preterm labor indication at 24-34 weeks of gestation who are treated with nifedipine or MgSO4 for tocolysis

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:-Patients with preterm labor indication at 24-34 weeks of gestation -Treated with nifedipine or MgSO4 for tocolysis Exclusion Criteria: * Multiple pregnancy * premature rupture of membranes * Chorioamnionitis * Placental abruption * Severe fetal growth restriction * Congenital anomalies of the fetus * Preeclampsia * Oligohydramnios * Maternal diabetes * Contraindications for the use of nifedipine and/or MgSO4 in the mother

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unexpected fetal cardiac effects of nifedipine and MGSO4 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unexpected fetal cardiac effects of nifedipine and MGSO4

Contacts and locations

Locations

  • Şanlıurfa Training and Research Hospital

    Sanliurfa, 63100, Turkey (Türkiye)